Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INM-755 in Epidermolysis Bullosa
NCT04908215Phase 2Completed
- Sponsor
- InMed Pharmaceuticals Inc.
- Start
- Dec 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in epidermolysis bullosa (EB) comparing INM-755 cream with Vehicle cream (2 arms). Primary endpoints: Change from Baseline in Non-Wound Itch by Visual Analogue Scale (VAS) at 28 days, Change from Baseline in Wound Surface Area at 28 days and 3 more. Started Dec 2021; status: completed.
02
Drugs
cannabinol topical
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT04908215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908215.